Haemonetics Stock Investor Sentiment

HAE Stock  USD 62.99  8.25  11.58%   
About 55% of Haemonetics' investor base is interested to short. The analysis of overall sentiment of trading Haemonetics stock suggests that many investors are impartial at this time. The current market sentiment, together with Haemonetics' historical and current headlines, can help investors time the market. In addition, many technical investors use Haemonetics stock news signals to limit their universe of possible portfolio assets.

Comfort Level 45

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Haemonetics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Haemonetics.

Haemonetics Historical Sentiment

Although Haemonetics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Haemonetics, such as negative comments on social media and news outlets, may cause fear in the market and push Haemonetics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Haemonetics.
  

Haemonetics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Haemonetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Haemonetics Historical Investor Sentiment

Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Haemonetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Haemonetics.

Haemonetics Maximum Pain Price Across March 21st 2025 Option Contracts

Haemonetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Haemonetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Haemonetics' options.
over a month ago at zacks.com         
Reasons to Ratain CVS Stock in Your Portfolio Now
zacks News
over a month ago at zacks.com         
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
zacks News
over a month ago at finance.yahoo.com         
HAE or SYK Which Is the Better Value Stock Right Now?
Yahoo News
over a month ago at finance.yahoo.com         
LH Stock May Gain From Select MAWD Pathology Asset Purchase Deal
Yahoo News
over a month ago at finance.yahoo.com         
SNN Stock Might Rise Following FDA Nod for AETOS Stemless
Yahoo News
over a month ago at finance.yahoo.com         
ZBH Stock Might Rise Following FDA Nod for OsseoFit
Yahoo News
over a month ago at prnewswire.com         
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema
prnewswire News
over a month ago at finance.yahoo.com         
Blood Market to Grow by USD 2.6 Billion , Report on AI-Driven Market Transformation and Growth in Ho...
Yahoo News
over a month ago at finance.yahoo.com         
Omnicell Introduces OmniSphere Platform, Stock to Gain
Yahoo News
over a month ago at finance.yahoo.com         
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
Yahoo News
over a month ago at businesswire.com         
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase ...
businesswire News
over a month ago at kalkinemedia.com         
Global Blood Collection Devices Market to Register Incremental Growth at a CAGR of 7 percent by 2030...
news
over a month ago at zacks.com         
Should You Continue to Retain Insulet Stock in Your Portfolio Now?
zacks News
over a month ago at zacks.com         
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
zacks News
over two months ago at seekingalpha.com         
Haemonetics started at overweight by J.P. Morgan
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Haemonetics that are available to investors today. That information is available publicly through Haemonetics media outlets and privately through word of mouth or via Haemonetics internal channels. However, regardless of the origin, that massive amount of Haemonetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Haemonetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Haemonetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Haemonetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Haemonetics alpha.

Haemonetics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Haemonetics started at overweight by J.P. Morgan
12/06/2024
2
Reasons to Ratain CVS Stock in Your Portfolio Now
12/19/2024
3
Veracyte Gains 44 percent in a Year Whats Driving the Stock
01/06/2025
4
Microbot Medical Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
01/13/2025
5
Haemonetics Corp Completes Sale of Whole Blood Assets to GVS S.p.A
01/14/2025
6
Are You a Growth Investor This 1 Stock Could Be the Perfect Pick
01/17/2025
7
Analysts Set Haemonetics Co. PT at 108.78
01/22/2025
8
Heres Why Haemonetics is a Strong Value Stock
01/24/2025
9
Disposition of 161 shares by Roy Galvin of Haemonetics at 71.48 subject to Rule 16b-3
01/28/2025
10
DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise
01/30/2025
11
Haemonetics Q3 2025 Earnings Preview
02/05/2025
12
Haemonetics stock slides on revenue miss
02/06/2025

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Fundamental Analysis
View fundamental data based on most recent published financial statements